前列腺素E1与多巴酚丁胺联合治疗充血性心力衰竭临床观察

前列腺素E1具有多种生理功能,大量临床研究证明前列腺素E1可阻止心力衰竭(心衰)发展,改善症状和体征。我院近年应用前列腺素E1(PGE1)与多巴酚丁胺联合治疗慢性心衰,可有效改善心功能。现报告如下。1对象和方法1·1对象选择2005年4月~2006年5月我院心内科住院心衰患者共80例,用简单随机法分为治疗组和对照组。治疗组男26例,女14例;年龄31~79岁,平均52·7岁;其中冠心病20例,肺源性心脏病(肺心病)9例,高血压性心脏病(高心病)6例,心脏瓣膜病3例,扩张型心肌病2例。对照组男22例,女18例;年龄29~80岁,平均年龄53·1岁。其中冠心病21例,肺心病9例…     

多巴酚丁胺联合多巴胺治疗慢性肺原性心脏病难治性心力衰竭

多巴酚丁胺联合多巴胺治疗慢性肺原性心脏病难治性心力衰竭赵中苏粟奇志韩建中难治性心力衰竭（心衰）是指经卧床休息、低钠饮食、利尿剂、洋地黄和血管扩张剂等常规治疗无效的心衰。我们１９９３年以来用多巴酚丁胺联合多巴胺治疗３６例慢性肺原性心脏病（肺心病）难治性...     

多巴酚丁胺联合酚妥拉明治疗28例顽固性心力衰竭的临床研究

我院于1988年3月至1991年8月联合应用多巴酚丁胺(dobutamine)和酚妥拉明治疗顽固性心衰28例,疗效显著,无明显副作用,现报道如下。材料与方法本组28例均为1988年3月至91年8月我院内科收治的顽固性心衰病人,其中男11例,女17例;年龄15～71岁,平均37.9±15.3岁。28例中风心病7例、肺心病5例、冠心病12例(包括急性心肌梗塞1例、陈旧性心肌梗塞3例)、高心病3例、扩张型心肌病1例。发生心衰时间最长10年,最短3天,平均2.2±1.1年。心功能分级按纽约心脏病协会(NYHA)标准,均属4级。采用多巴酚丁胺40mg及酚妥拉明10～20mg加入5～10％葡萄糖250ml中,3小时左右滴完,平均多巴酚丁胺约4.8μg/kg/min,酚妥拉明约1.2～2μg,/kg/min,每天一次,疗程不定。血压低于10.6/6.7kPa不     

多巴胺、多巴酚丁胺治疗顽固性心力衰竭临床观察

目的观察多巴胺与多巴酚丁胺联合治疗顽固性心力衰竭的效果。方法将40例顽固性心力衰竭患者随机分为对照组与治疗组,对照组20例按心力衰竭常规综合治疗,治疗组20例在常规综合治疗的基础上加用多巴胺与多巴酚丁胺静脉注射治疗。结果治疗组显效率55%,有效率40%,总有效率为95%;对照组显效率30%,有效率40%,总有效率为70%,两组疗效对比有统计学意义(2χ=7.9,P<0.01)。结论多巴胺与多巴酚丁胺联合治疗顽固性心力衰竭疗效好,副作用小。     

“多巴酚丁胺”治疗心力衰竭的护理

我院循环科于1988年至今用多巴酚丁胺治疗心衰28例。男15例;女13例,年龄26—78岁,平均48.5岁。病因:冠心病10例;高心病3例;风心病房(?)8例;扩张型心肌病3例;肺心病4例;Ⅲ。心衰者10例。应用多巴酚丁胺治疗后均得到良好的效果,其方     

静脉滴注多巴酚丁胺的观察与护理

多巴酚丁胺有强大的正性肌力作用，并一直成功地用来治疗充血性心力衰竭病人。本药是选择性正性肌力用药，对心衰和周围血管的影响较小。治疗剂量能增加心肌收缩力和心输出量，而对心衰的影响不大，故引发心律失常的可能性较小，耗氧量增加也不多。临床对心梗后或心脏手术后排出量低的患者疗效优于异丙肾上腺素，且作用效安全，用于心排出量低和     

美托洛尔治疗风湿性心脏病慢性心力衰竭患者的疗效分析

目的探讨美托洛尔治疗风湿性心脏病慢性心力衰竭患者的临床疗效及安全性。方法选取风湿性心脏病慢性心力衰竭患者100例,采用随机数字表法分为研究组和对照组。对照组给予常规治疗,研究组在常规治疗基础上加用美托洛尔。结果与对照组相比,研究组治疗后总有效率显著提高,差异有统计学意义(P0.05)。治疗后,两组患者的SBP、DBP值有显著下降,但在正常值内;两组6 min步行距离与治疗前相比显著增加,LVEF值明显升高,组间比较显示,研究组患者上述指标改善程度明显优于对照组(P0.05)。两组患者在治疗期间均未出现明显的不良反应。结论美托洛尔与常规治疗结合可提高风湿性心脏病慢性心力衰竭患者的临床疗效,有效改善心功能,降低NYHA分级,安全性较高,具有较高的临床价值。     

风湿性心脏病合并心力衰竭患者内皮素及血管性血友病因子水平的变化

目的　探讨风湿性心脏病合并充血性心力衰竭 (RHD CHF)患者内皮素 (ET 1)及血管性血友病因子(vWF)的变化及其意义。方法　检测 31例CHF患者和 30名正常人ET 1、vWF ,并按心功能等级分组进行比较分析。结果　RHD CHF患者血浆ET 1、vWF水平与对照组比较明显升高 (P <0 .0 1) ,且心功能越差 ,ET 1、vWF水平越高 ,心功能Ⅲ、Ⅳ级与Ⅱ级比较显著升高 (P <0 .0 5 ,P <0 .0 1) ;患者血浆ET 1与vWF呈正相关 (r=0 .6 6 8,P <0 .0 1)。结论　RHD CHF的发生、发展与细胞内皮损伤有关 ,检测血浆中vWF和ET 1可作为评价CHF病情严重程度的指标之一。     

风湿性心脏瓣膜病心功能不全与脂质过氧化物和红细胞变形能力改变的研究

目的：探讨风湿性心脏瓣膜病心功能改变与脂质过氧化物（LPO），红细胞变形能力（RCD）的变化。方法：将心功能不全的风湿性心脏瓣膜病患者按心功能不全程度分3组共115例，健康对照组50例，检测血清LPO及RCD的改变。结果：心功能Ⅳ级组比Ⅲ级组，Ⅲ级比Ⅱ级组的LPO增加及RCD下降，有高度显著性差异（P＜0．01），心功能不全3组LPO的增加，RCD的下降与对照组相比亦有显著性差异（P＜0．01），而LPO与RCD呈直线相关，3组相关系分别为0．304，0．336，0．453（P均＜0．01），结论：风湿性心脏瓣膜病随心功能减退存在着LPO升高及RCD的下降，二者改变可能参与风湿性心脏瓣膜病患者心功能变化。     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.     

前列腺素E1联合硫酸镁在肺心病急性加重期应用中的临床研究

Objective To study the curative effect and medchanism of action about prostaglandin E1 and magnesium sulfate in the treatment of chronic pulmonary heart disease in the aggravation period. Methods Fifty-three patients with chronic pulmonary heart disease in the aggravation period were accepted emergencyward in the Guangzhou Red Cross Hospital during June 2007 to May 2008,they were randomly divided into the treatment group (28 case) and control group (25 case) . Both groups were given low flux breathe in oxygen and dissipate phlegm and relieve a cough and resist infection and spasmo]ysis and calm down asthma and strive heart and diuresis colligate therapy. Mean while,patients in the treatment group,beside the colligate therapy,were treated with prostaglandin E1 10 ml and magnesium sulfate 10 ml ,the course of treatment lasted 2 weeks. Then we investigate the amelioration of clinical symptom and alteration of blood gas analysis in the two groups before and after the treatment. Results The rate of clinical efficacy were 89.3% (25/28) and 76.0% (18/25),with superiority in the treatment group (χ2=1.87,P<0.05) . Whole blood viscosity,fibrinogen,PaO2 and PaCO2 were improved in both groups,amelioration of blood gas analysis observation superiority in the treatment group compared with control group (P<0.05). Conclu-sions Prostaglandin E1 and magnesium sulfate can depress pulmonary artery pressure and abate the afterload of right ventricle,which have better treatment effect in chronic pulmonary heart disease in the aggravation period.